Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average PT from Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has been given a consensus recommendation of “Buy” by the six analysts that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $34.50.

Several brokerages have recently weighed in on CAPR. Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Main Street Financial Solutions LLC boosted its holdings in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter worth about $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics during the second quarter valued at approximately $147,000. The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $192,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

CAPR opened at $14.08 on Thursday. The company’s 50 day moving average is $17.36 and its 200 day moving average is $10.57. The company has a market cap of $640.22 million, a price-to-earnings ratio of -13.28 and a beta of 3.98. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.